This article was originally published in The Rose Sheet
Executive SummaryBlistex President & Chief Operating Officer Richard Green named chairman-elect by the board during a telephone vote Feb. 8. Green was first elected to the board in 1994 and joined the executive committee in 1997. He will succeed current chairman Michael Valentino upon completion of his term. Valentino's current one-year term ends in May. A chairman "may or may not" seek reelection upon completion of his term, CHPA notes. However, to be elected, an individual must be employed by an active member firm; Valentino recently left his position as Novartis global head OTC/exec VP...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.